Japan’s Ministry of Health, Labor and Welfare (MHLW) on October 2 ordered a safety-related label revision for Clinigen’s anticancer drug Leustatin (cladribine) to advise against breastfeeding for seven days after treatment. The revision will affect the breastfeeding subsection under precautions…
To read the full story
REGULATORY
- MHLW Drug Supply Monitoring System Hit by Cyberattack, Possible Data Leak
November 19, 2026
- Expert Calls for Remote MRI Reviews to Monitor Alzheimer’s Drug Risks
November 18, 2026
- Japan Implements ICH Bioequivalence Guideline for Immediate-Release Oral Drugs
November 18, 2026
- MHLW Eyes Bigger Push for Regional Formularies in FY2030–FY2035 Cost Plan
November 18, 2026
- Japan Approves Boey, Wider Labels for Hernexeos, Rinvoq, Tukysa, Pluvicto, and More
November 17, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





